Viewing records where tag name contains "media" View All

COVID-19: Viraleze Nasal Spray Highly Effective Against Alpha, Beta And Gamma Variants

Jun 19th, 2021

"New data released on June 18 showed that Australia’s Viraleze anti-COVID nasal spray is more than 99.99 per cent effective against three of the four variants of the SARS-CoV-2 virus," as reported by Republic World. Read the full article here.

Read More

Latest Testing Confirms Viraleze Highly Effective Against Alpha, Beta and Gamma COVID Variants

Jun 18th, 2021

News18 reports on Starpharma's latest VIRALEZETM announcement: "New data released today shows that Australia’s Viraleze anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus." Read the full article here.

Read More

Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

Jun 18th, 2021

Markets Insider features Starpharma's latest announcement, ..."The results hold significant promise for Viraleze™ – developed by Melbourne-based biopharmaceutical company Starpharma (ASX: SPL) – in the fight against new and emerging variants of SARS-CoV-2, as several countries begin their long-awaited opening of international borders..." Read the full article here

Read More

Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

Jun 18th, 2021

"New data released today shows that Australia's Viraleze™ anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus," as reported by the New Delhi Times. Read the full article here.

Read More

Starpharma (ASX:SPL) shows 99.9pc antiviral activity against three COVID-19 variants

Jun 18th, 2021

"Starpharma's (SPL) SPL7013 drug has shown a reduction of more than 99.9 per cent against the Alpha, Beta and Gamma SARS-CoV-2 variants," The Market Herald reports. Read the full article here.

Read More

Scripps Research Institute testing shows Viraleze highly active against UK COVID strain

Jun 1st, 2021

Markets Insider featured Viraleze and Starpharma following the announcement of SPL7013's potent antiviral activity against the UK coronavirus variant. Read the full article here

Read More

Starpharma (ASX:SPL)'s nasal spray achieves 98% efficacy against COVID-19

Jun 1st, 2021

"Biopharmaceutical company Starpharma (ASX:SPL) claims the company’s nasal spray product is a highly efficacious means of protection from the UK variant of the coronavirus," Finance News Network reports. Read the full article here

Read More

Starpharma (ASX:SPL) shows 98pc antiviral activity against U.K COVID-19 variant

Jun 1st, 2021

The Market Herald reports on Starpharma's latest announcement: "Starpharma (SPL) has confirmed that its SPL7013 drug has potent antiviral activity against the U.K. SARS-CoV-2 variant.

"In laboratory studies, SPL7013 achieved a reduction of more than 98 per cent against the virus."

Read the full article here. 

Read More

Tackling Covid: How the Harlequins are defending themselves

May 22nd, 2021

Twickenham Nub News interviewed Harlequins’ Head of Medical Services, Mike Lancaster, about the partnership with Viraleze. "The Harlequins’ long-awaited return to Twickenham Stoop has seen the team make many changes to ensure players’ safety.

"Alongside several changes at the stadium, the team has also started defending itself with a new nose spray, Viraleze." Read the full article here. 

Read More

Tax incentives to encourage innovation

May 18th, 2021

Dr Jackie Fairley, CEO of Starpharma discusses the Australian governments proposals for a 'patent box' and what it will mean for the company and Australian innovation in general. Watch here. (ausbiz account required)

Read More

Harlequins Partners with Anti-Viral Nasal Spray Viraleze

May 11th, 2021

Sport Industry Group featured the announcement of Starpharma's VIRALEZETM partnership with Harlequins. "Harlequins has announced a new partnership with antiviral nasal spray VIRALEZETM, which the club says it will use as one part of its suite of measures put in place to help protect its players and coaching staff." Read more here.

Read More

Harlequins Partners Antiviral Nasal Spray Brand Viraleze

May 11th, 2021

iSportconnect reported on the new partnership between Starpharma's antiviral nasal spray, VIRALEZETM, and Harlequins, a professional rugby union team in the UK. Read more here

Read More

Starpharma (ASX:SPL) launches antiviral nasal spray in Europe

May 6th, 2021

The Market Herald reported on Starpharma's launch of VIRALEZE™  in Europe. Read the full article here.

  • Starpharma’s (SPL) antiviral nasal spray is now available for purchase by consumers in Europe via the company’s online store
  • VIRALEZE is a broad spectrum antiviral nasal spray, which studies have shown can inactivate more than 99.9 per cent of coronavirus pathogens within one minute
  • The product is already available online in the U.K. and through Lloyds Pharmacy’s 1400 stores, with the company now pursuing avenues to provide rapid access for VIRALEZE in India
  • Starpharma shares are up 3.93 per cent, trading at $1.85

 

Read More

Australian company develops a $27 anti-viral nasal spray that 'deactivates' Covid - and it's being used right across the UK

May 4th, 2021

Eliza McPhee for Daily Mail Australia reported: An Australian biotech company has joined the fight against coronavirus by launching an anti-viral nasal spray that's already available in the UK. Read the article here

  • Biotech company Starpharma has launched anti-viral nasal spray in the UK
  • It acts as a barrier to coronavirus, trapping it in the nose and inactivating virus
  • Spray best used once every six hours for up to 30 days, CEO Jackie Fairley says
  • Melbourne-based company says it has plans to launch product soon in Australia 
Read More

Starpharma (ASX:SPL) spends March quarter developing VIRALEZE

Apr 28th, 2021

Starpharma featured in The Market Herald following the announcement of Starpharma's Quarterly Cashflow and Activities Report. Read more here

Read More

GlaxoSmithKline hoping to deliver Australia’s next COVID treatment

Apr 16th, 2021

Starpharma featured in The Sydney Morning Herald's daily COVID-19 update, as reported by Emma Koehn: ASX-listed companies have pivoted swiftly towards virus treatments and preventative in the past year, including Melbourne-based Starpharma which successfully brought a nasal spray to market in the UK last month. Read more here

Read More

Aussie virus killer not to be sneezed at

Apr 11th, 2021

The Australian interviewed Dr Jackie Fairley, Starpharma CEO, about the recent launch of Viraleze in the UK. "As the nation hyperventilates over a delay in the vaccine rollout, Starpharma is rolling out a new line of defence against the coronavirus in global markets." Read more here. (Behind paywall)

Read More

LloydsPharmacy launches nasal spray designed to fight coronavirus

Mar 30th, 2021

The Grocer reported on the launch of VIRALEZE in LloydsPharmacy across the UK. It launches online this week, ahead of an in-store rollout from April. Read more here.

Read More

Covid antiviral nasal spray available from Lloyds

Mar 30th, 2021

Pharmacy Magazine UK reported on the launch of VIRALEZE in the UK. A novel nasal spray available exclusively from LloydsPharmacy. The UK will be the first country to launch this product. Read more here.

Read More

Lloyds Pharmacy offering first-ever Covid nasal spray Viraleze that 'blocks 99.9% of germs'

Mar 30th, 2021

CambridgeshireLive featured news of the VIRALEZE launch in the UK. A groundbreaking Covid nasal spray called Viraleze is now available to buy online. Lloyds Pharmacy is rolling out the UK's first-ever nasal spray specifically designed to fight coronavirus. Read more here

Read More

VIRALEZE™ featured on Sky News

Mar 29th, 2021

Sky News interviewed Starpharma CEO Dr Jackie Fairley upon launch of VIRALEZE™ at LloydsPharmacy in the UK. Dr George Kinghorn, Infectious Disease Adviser and former Clinical Director of the Sheffield Teaching Hospitals NHS Foundation Trust was also interviewed for further commentary on VIRALEZE™.

 

Read More

Starpharma to launch anti-COVID nasal spray with major UK pharmacy chain

Mar 25th, 2021

Business News Australia reported VIRALEZE will be stocked by LloydsPharmacy in the UK. It will first be made available at LloydPharmacy's online store and is expected to be instore in April. Read more here.

Read More

Aussie biotech Starpharma signs deal to sell COVID nose spray in Britain

Mar 25th, 2021

The Age reported Australian biotech Starpharma is taking its COVID-fighting antiviral nasal spray to the world, signing a deal with UK chemist chain LloydsPharmacy to sell the product in Britain as the country emerges from lockdown. Read more here

Read More

Starpharma (ASX:SPL) reports DEP HER2-lutetium shows potent anticancer effect

Mar 16th, 2021

Finance News Network reported that Starpharma's second radiopharmaceutical candidate, DEP HER2-lutetium, achieved potent and durable anticancer activity, with complete tumour regression, outperforming Herceptin labelled with lutetium, in a breast cancer model. Read more here

Read More

Starpharma (ASX:SPL) shares rise on breast cancer development

Mar 16th, 2021

The Market Herald reported that Starpharma's second radiopharmaceutical candidate, DEP HER2-lutetium, had achieved anti-cancer activity in breast cancer, and that the drug outperformed Herceptin, a treatment for a type of breast cancer called HER2 positive. Read more here

Read More

Starpharma Up With News, Down With None; Timing Entry Makes Sense

Feb 25th, 2021

Seeking Alpha, a financial market portal featured an update Starpharma, including the European registration of its VIRALEZE™ antiviral nasal spray. To read the full article click here.

Read More

Channel 7 News reports Starpharma's VIRALEZE has been registered in the UK/Europe

Feb 23rd, 2021

Channel 7 News (Melbourne) reports Starpharma's VIRALEZE™ has been registered in the UK/Europe. Watch here

Read More

Starpharma signs research agreement with MSD

Feb 12th, 2021

The Market Herald reported that Starpharma signed a Research Agreement with Merck & Co., Inc., Kenilworth NJ USA for dendrimer-based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP® technology. Read more here

Read More

Ausbiz interviews Starpharma CEO Dr Jackie Fairley

Feb 10th, 2021

Finance and market news website AusBiz interviewed Starpharma CEO Dr Jackie Fairley to discuss the global expansion of AstraZeneca’s clinical trial for AZD0466 and their multi-product DEP® licence with Starpharma. She also spoke about the upcoming launch of VIRALEZE in Europe. Watch the interview here.

 

Read More

Aussie condom antiviral recruited for Covid-19 fight

Feb 4th, 2021

The Australian interviewed Starpharma CEO Dr Jackie Fairley regarding Starpharma’s plans for the European launch of VIRALEZE™ antiviral nasal spray. Read article here.

Read More

Australian-developed COVID nasal spray set to land in Europe

Feb 4th, 2021

Biotech Dispatch reported on Starpharma's launch plans for VIRALEZE™ in Europe. Read the full article here.

Read More

Channel 7 evening news features Starpharma's VIRALEZE

Feb 3rd, 2021

Watch Laurel Irving Channel 7 News (Melbourne) interview Dr Jackie Fairley, CEO of Starpharma about VIRALEZE™ and the need for other COVID-19 preventative tools alongside vaccines. 

Read More

Starpharma prepares to launch COVID-killing nasal spray

Feb 2nd, 2021

Alan Kohler spoke with Dr Jackie Fairley, CEO of Starpharma about the launch of its VIRALEZE™ antiviral nasal spray, for the Eureka Report. Listen to the interview here.

Read More

Leading broker names the ASX healthcare shares to buy in 2021

Jan 9th, 2021

The Motley Fool reported that Starpharma has been named by analysts at Bell Potter "one of ASX shares from several industries that they believe are best placed to have a strong 2021".

To read the full article, click here

Read More

Starpharma Viraleze: COVID-19 Nasal Spray Development

Nov 20th, 2020

Seeking Alpha, a financial market portal featured a piece on Starpharma’s latest update on its VIRALEZE™ COVID-19 nasal spray. The article noted the potential of the spray and Starpharma’s latest regulatory developments on this front. To read the full article click here.

Read More

Starpharma (ASX:SPL) banks $5.7M government R&D tax refund

Oct 21st, 2020

The Market Herald reported that Starpharma are to receive a $5.7 million research and development (R&D) tax incentive refund from the Federal Government following the government’s program to  support companies taking on R&D that benefits Australia. To watch the full video click here.

Read More

Biotech In Focus In 2020

Oct 16th, 2020

Online financial news platform FN Arena recently published an article which highlighted six biotech ASX-listed companies that have recently been viewed positively by analysts. Starpharma was listed as one such company, stating that Bell Potter had emphasized the company’s strong growth potential. To read the full article click here

Read More

$2B R&D win for biotech, resources

Oct 8th, 2020

Starpharma was featured in an article by Stockhead, an online publication that delivers news on ASX-listed small and mid-cap companies. The piece looked at the Federal Government’s decision to abandon plans to reduce R&D tax refund by $1.8B, and will instead add $200M in value to the incentive. The article noted Starpharma received a $4.9M tax refund in December 2019 for R&D associated with the development of its DEP drug delivery system and VivaGel BV women’s health products.

To read the full article click here.

 

Read More

Allianz ups Starpharma stake as M&G sells

Oct 8th, 2020

On 8 October, Starpharma was included in the SMH’s live market update which reported Allianz Global Investors had upped its stake in Starpharma after buying close to 10 million additional shares. It added that the fund’s position in the company had risen from 5 to 7.1 per cent. To read the full article click here

Read More

Starpharma is interviewed by Stockhead to give a company overview and provide an update on its COVID-19 nasal spray

Sep 17th, 2020

Stockhead’s Tim Boreham interviewed Starpharma CEO Jackie Fairley for their Health Kick Podcast. Tim reported that Starpharma has gone from strength to strength following progress on its COVID-19 nasal spray. To hear an overview of the company, and update on current development programs and plans for the year ahead, listen to the full episode here

Read More

2GB’s Jim Wilson interviews Starpharma CEO Dr Jackie Fairley

Aug 26th, 2020

2GB radios Jim Wilson interviewed Starpharma CEO Dr Jackie Fairley to get an update on how Starpharma is fast-tracking a nasal spray designed to be used as a preventative measure in the fight against COVID-19.

To listen to the full interview click here.

Read More

ABC News features Starpharma on ‘The Kohler Report’

Aug 26th, 2020

Starpharma was featured on ABC’s  finance news segment ‘The Kohler Report’, where Alan Kohler highlighted that Starpharma shares had risen 23% following the Company’s update on its SPL7013-based antiviral nasal spray, which has shown to have potent antiviral activity against COVID-19. The update included that Starpharma has commenced confidential commercial discussions with related parties.

To watch the full report, click here.

Read More

Australian Manufacturing writes about Starpharma identifying a manufacturer of its antiviral nasal spray for COVID-19

Aug 26th, 2020

Starpharma was recently featured in an article by Australian Manufacturing, a leading publication and resource for the manufacturing and industrial sector in Australia. The article noted Starpharma had undertaken a pilot manufacture for its SPL7013 antiviral nasal spray, which has been tested and confirmed to have potent antiviral activity against SARS-CoV-2, the virus that causes COVID-19. The article also highlightsed SPL has identified a manufacturer and are currently compiling documentation in preparation for regulatory submission.

To read the full article click here.

Read More

The Age: Starpharma CEO Dr Jackie Fairley on Australia’s need to turn homegrown research into commercial products

Jul 3rd, 2020

The Age interviewed Starpharma CEO Dr Jackie Fairley about how the COVID-19 pandemic could be the much needed catalyst for the pharmaceutical industry to improve the way they convert important research into commercial products. Dr Fairley also covered Starpharma’s recent activities in response to the pandemic including, the development of a nasal spray product using the antiviral dendrimer, SPL7013.

To read the full interview click here.

Read More

The 7.30 report interviews Starpharma CEO Dr Jackie Fairley

Jun 25th, 2020

The ABC’s 7:30 report interviewed Starpharma CEO Dr Jackie Fairley to discuss the importance of creating COVID-19 preventative products while the world waits for a vaccine to be developed. Dr Fairley discussed how Starparma’s patented dendrimer SPL7013 has shown significant anti-viral activity against SARS-CoV-2 (coronavirus) and how quickly a product using this ingredient could be brought to market given its approval and use in other marketed products.

Watch the full interview click here.

Read More

Ausbiz interviews Starpharma CEO Dr Jackie Fairley

Jun 19th, 2020

Finance and market news website AusBiz interviewed Starpharma CEO Dr Jackie Fairley to discuss the company’s first radiotherapeutic candidate, DEP® lutetium. The candidate showed highly statistically significant anticancer activity, tumour regression and 100% survival in a human prostate cancer model. The interview also covered the company’s latest VivaGel® BV launch in Central and Eastern Europe.

To watch the full interview click here.

 

Read More

SBS speaks to Starpharma CEO Dr Jackie Fairley on female representation in business

Jun 19th, 2020

A new study using Australian data showed a causal link between female leadership and business performance. Starpharma is one of only 15 ASX300 companies to have a female CEO and Dr Jackie Fairley spoke with SBS about the importance of having senior female leaders in a corporate setting.

For the full interview click here.

Read More

Starpharma CEO Dr Jackie Fairley on Proactive Investors (Canada)

May 18th, 2020

The Canadian arm of finance news network Proactive Investors recently interviewed Starpharma CEO Dr Jackie Fairley to discuss the Company's DEP® portfolio and the recent news that Starpharma is investigating product concepts for proprietary dendrimer SPL7013 in relation to COVID-19.

Watch the full interview here: https://www.youtube.com/watch?v=jqn06bUymDw&feature=youtu.be

Read More

Starpharma CEO Dr Jackie Fairley on ausbiz

May 11th, 2020

Finance and market news website AusBiz co-founders Kylie Merritt and David Koch interviewed Starpharma CEO Dr Jackie Fairley to discuss DEP® irinotecan moving into Phase 2 and how Starpharma is investigating product concepts for SPL7013 in the fight against COVID-19.

To watch the full interview click here

Read More

Australia’s biotech sector tests multiple agents to fight COVID-19

Apr 22nd, 2020

US biotech publication BioWorld noted that a number of Australian biotech companies have been testing agents in the fight against COVID-19, in particular highlighting Starpharma’s SPL7013 which showed significant positive antiviral activity against the SARS-CoV-2 virus.

To read the full article, click here

Read More